Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAT2203 in Refractory Mucocutaneous Candidiasis
NCT02629419Phase 2Completed
- Sponsor
- Matinas BioPharma
- Start
- Sep 2016
- Primary completion
- Nov 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MAT2203 in chronic mucocutaneous candidiasis (CMC), sponsored by Matinas BioPharma. Started Sep 2016; status: completed.
02
Drugs
MAT2203
03
Conditions
chronic mucocutaneous candidiasis (CMC)
Beyond the preview
Go deeper on NCT02629419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629419.